These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2643621)

  • 41. Antimicrobial susceptibility testing of anaerobic bacteria: review and update on the role of the National Committee for Clinical Laboratory Standards.
    Thornsberry C
    Rev Infect Dis; 1990; 12 Suppl 2():S218-22. PubMed ID: 2406873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
    Goldstein EJ; Citron DM; Warren Y; Tyrrell K; Merriam CV
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of sensititre broth microdilution and agar dilution susceptibility testing techniques for meropenem to determine accuracy, reproducibility, and predictive values.
    Dowzicky MJ; Nadler HL; Sheikh W
    J Clin Microbiol; 1994 Sep; 32(9):2204-7. PubMed ID: 7814547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterial.
    Ross JE; Scangarella-Oman N; Jones RN
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):437-9. PubMed ID: 23461830
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antimicrobial susceptibility of anaerobic bacteria in Australia.
    Chen SC; Gottlieb T; Palmer JM; Morris G; Gilbert GL
    J Antimicrob Chemother; 1992 Dec; 30(6):811-20. PubMed ID: 1289355
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial susceptibility testing of anaerobic bacteria.
    Rosenblatt JE
    Rev Infect Dis; 1984; 6 Suppl 1():S242-8. PubMed ID: 6372033
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of Sch 34343 and cefbuperazone against anaerobic bacteria.
    Shafran SD; Wong J; Chow AW
    Antimicrob Agents Chemother; 1985 May; 27(5):749-52. PubMed ID: 4015069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties.
    Kays MB; White RL; Friedrich LV; Del Bene VE
    Clin Ther; 1991; 13(5):596-605. PubMed ID: 1799917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibiotic susceptibility testing of anaerobic organisms using the agar dilution method: comparison of three techniques.
    Wexler HM; Reeves D; Finegold SM
    Clin Ther; 1988; 10(6):747-60. PubMed ID: 3219688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative in vitro study of the antibacterial effect of cefotetan against gram-positive and gram-negative aerobic and anaerobic strains from fresh clinical isolates.
    Klietmann W; Focht J; Nösner K
    Chemioterapia; 1987 Jun; 6(2 Suppl):92-3. PubMed ID: 3509542
    [No Abstract]   [Full Text] [Related]  

  • 51. Susceptibility testing of anaerobic bacteria: evaluation of the redesigned (Version 96) bioMérieux ATB ANA device.
    Dubreuil L; Houcke I; Singer E
    J Clin Microbiol; 1999 Jun; 37(6):1824-8. PubMed ID: 10325331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bactericidal activity of ceftizoxime, cefotetan, and clindamycin against cefoxitin-resistant strains of the Bacteroides fragilis group.
    Aldridge KE; Stratton CW
    J Antimicrob Chemother; 1991 Nov; 28(5):701-5. PubMed ID: 1778873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of cephalosporins for prophylaxis and therapy of polymicrobial infection in mice.
    Brook I
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1531-5. PubMed ID: 8363386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of agar dilution, microdilution, and disk elution methods for measuring the synergy of cefotaxime and its metabolite against anaerobes.
    Smith JA; Henry D; Ngui-Yen J; Castell A; Coderre S
    J Clin Microbiol; 1986 Jun; 23(6):1104-8. PubMed ID: 2872231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative in vitro activity of cefbuperazone against anaerobic bacteria isolated from community hospitals.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1985 Feb; 27(2):162-6. PubMed ID: 3985600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determination of susceptibility of anaerobic bacteria to cefotetan and cefoxitin by the thioglycolate disk elution method.
    Barry AL; Packer RR
    J Clin Microbiol; 1984 Nov; 20(5):912-6. PubMed ID: 6595259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anaerobic susceptibility testing. Slight differences in inoculum size can make a difference in minimum inhibitory concentrations.
    Aldridge KE; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Mar; 18(3):191-5. PubMed ID: 7924212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the E test for susceptibility testing of anaerobic bacteria.
    Citron DM; Ostovari MI; Karlsson A; Goldstein EJ
    J Clin Microbiol; 1991 Oct; 29(10):2197-203. PubMed ID: 1939571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cefotetan: a review of the microbiologic properties and antimicrobial spectrum.
    Jones RN
    Am J Surg; 1988 May; 155(5A):16-23. PubMed ID: 3287964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria.
    Borobio MV; Perea EJ
    Antimicrob Agents Chemother; 1984 Mar; 25(3):342-3. PubMed ID: 6721466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.